SCHEMBL709095

SCHEMBL709095

Cc1cccc(NC(=O)Nc2cccc(N)c2)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 2/20 0.79
SMN1; SMN2 Q16637 5/20 0.64
KMT2A Q03164 3/20 0.64
PKM P14618 1/20 0.64
ALDH1A1 P00352 3/20 0.64
SAE1 Q9UBE0 1/20 0.62
UBA2 Q9UBT2 1/20 0.62
HSD17B10 Q99714 1/20 0.61
NPC1 O15118 5/20 0.59
RAB9A P51151 5/20 0.59
POLB P06746 1/20 0.57
GBA1 P04062 1/20 0.57
MAPK1 P28482 1/20 0.57
MEN1 O00255 2/20 0.56
MAPT P10636 1/20 0.56
CASP3 P42574 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
CSF1R P07333 1/20 0.56
FLT1 P17948 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1657499 0.89 DDX3X (1.00) DDX3XSMN1; SMN2KMT2AALDH1A1NPC1
SCHEMBL30314470 0.89 DDX3X (1.00) DDX3XSMN1; SMN2KMT2AALDH1A1NPC1
SCHEMBL4416620 0.89 SMN1; SMN2 (0.77) SMN1; SMN2KMT2APKMALDH1A1SAE1
SCHEMBL29703055 0.89 SMN1; SMN2 (0.77) SMN1; SMN2KMT2APKMALDH1A1SAE1
SCHEMBL13724310 0.88 SAE1 (0.69) DDX3XSMN1; SMN2KMT2APKMALDH1A1
SCHEMBL14350754 0.88 DDX3X (0.77) DDX3XSMN1; SMN2KMT2APKMALDH1A1
SCHEMBL31054278 0.84 SMN1; SMN2 (0.75) SMN1; SMN2KMT2APKMALDH1A1SAE1
SCHEMBL259602 0.84 SMN1; SMN2 (0.75) SMN1; SMN2KMT2APKMALDH1A1SAE1
SCHEMBL711068 0.84 DDX3X (0.89) DDX3XSMN1; SMN2KMT2AALDH1A1HSD17B10
SCHEMBL5852140 0.82 SAE1 (0.76) SMN1; SMN2KMT2APKMALDH1A1SAE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108794408-B Pyrimidine phenylurea anti-tumor compound and preparation method and application thereof 中国医科大学 2020-04-21 CN disclosed
CN-108794408-A Pyrimidine phenylurea anti-tumor compounds and its preparation method and application 中国医科大学 2018-11-13 CN disclosed
US-8124759-B2 Inhibitors of protein kinases ABBOTT LABORATORIES (US) 2012-02-28 US disclosed
EP-2150553-B1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES ABBOTT LAB (US) 2011-10-05 EP disclosed
EP-2297151-A1 INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2011-03-23 EP disclosed
EP-2150553-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES Abbott Laboratories (US) 2010-02-10 EP disclosed
WO-2009136966-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-11-12 WO disclosed
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2009-05-21 US disclosed
US-20090023743-A1 INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (IL) 2009-01-22 US disclosed
WO-2008141145-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2008-11-20 WO disclosed
WO-2008141140-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131425-A1 INHIBITORS OF PROTEIN KINASES AURKC, AURKB, PLK1 DDX3X 1508/4885SMN1; SMN2 2414/4885KMT2A 1632/4885
US-20090023743-A1 INHIBITORS OF PROTEIN KINASES AURKC, AURKB, PLK1 DDX3X 1508/4885SMN1; SMN2 2414/4885KMT2A 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.